Weaning Approaches for Vasopressin in Sepsis

What Was Tested

In this phase 3 trial, researchers set out to test Vasopressin.

It had two arms (groups): Titrated group (experimental) and Abrupt group (active comparator).

The registry classes the interventions as other.

More on the Plan

Catecholamine infusions are usually tapered gradually in a titrated manner.

However, little is known about how to manage adjunctive therapies such as vasopressin.

While catecholamines have a short half-life (2-3 minutes), vasopressin's half-life ranges from 10 to 20 minutes.

Although endogenous vasopressin levels are depleted in the early phase of shock, they are restored during recovery.

Who Took Part

The registry lists 82 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age over 18 years. Admitted to the Intensive Care Unit. Patients with vasopressor dependent sepsis. Receiving combined norepinephrine and vasopressin therapy.

The full record lists 4 inclusion and 2 exclusion criteria.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

The participants were allocated by chance, so the Vasopressin group and the comparison group should start out alike.

The Vasopressin group and the comparison group ran side by side rather than switching.

Everyone knew when Vasopressin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2025-10-01 with completion listed for 2027-12-31.

It ran at 1 site in Brazil.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Hypotension within the first 24 hours (time frame: 24 hours).

It also tracked 9 secondary outcomes, for example Hypotension stratified according to vasopressin duration, Hypotension within the first hour, Vasopressor-free days, Vasopressin-free days, Renal replacement therapy and Cardiac arrhythmias.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Vasopressin in 82 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Vasopressin compound page, all human trials.